Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Nov 15 - Nov 20
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents Dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/glucagon-like peptide-1 receptor (GLP-1R) agonists are an emerging class of therapeutics for the treatment of obesity and diabetes that reportedly offer superior weight loss and glycemic control over their GLP-1R agonist (GLP-1RA) monotherapy predecessors
It is generally prescribed for individuals classified as obese with a BMI of 30 or higher, or for those overweight with a BMI of 27 or higher and with a weight-related health condition
Frontiers in Endocrinology , 2024
At lower doses the risk may be smaller, but strength training and adequate protein intake are non-negotiable complements to treatment
US$ 20.35
US$ 20.16
US$ 24.36
US$ 21.28
US$ 25.58
US$ 27.49
US$ 20.69
US$ 27.26
US$ 20.25
